TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00878254
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin: 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3 per study protocol.
Study: NCT00878254
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 1,200 mg/m\^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
Study: NCT00181155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 50 ml dose of 5% dextrose
Study: NCT01697722
Drug: Extra-fine hydrofluoroalkane-beclometasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
Study: NCT03635853
Drug: drug containing extract from cock's comb
Approvals — FDA: no, EMA: no, PMDA: no
Description: a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
Study: NCT02260557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching selexipag 200 μg tablets to be administered orally twice daily
Study: NCT01548287
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5213 doseA daily
Study: NCT03651674
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients only have antipsychotic drugs
Study: NCT01548287
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5213 doseB daily
Study: NCT01548287
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5213 doseC daily
Study: NCT00841256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
Study: NCT02959905
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
Study: NCT02959905
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
Study: NCT04164888
Drug: CIVI 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypercholesterolemia agent
Study: NCT04098874
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks postpartum of blinded placebo
Study: NCT01080742
Drug: Lodoz (Combination of bisoprolol and hydrochlorothiazide)
Normalized name: caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
Study: NCT04045665
Drug: Antiplatelet-only strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study: NCT04045665
Drug: Oral Anticoagulant plus background antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study: NCT00809042
Drug: L-carnitine and hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
Study: NCT00809042
Drug: hydroxyurea and magnesium chloride
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
Study: NCT00809042
Drug: hydroxyurea,L-carnitine and magnesium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
Study: NCT01349556
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tretinoin 0.025% cream
Study: NCT02901925
Drug: ABY-029
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
Study: NCT00238173
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
Study: NCT00239538
Drug: telmisartan combined with hydrochlorothiazide (80/12.5 mg)
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00239538
Drug: valsartan combined with hydrochlorothiazide (160/12.5mg)
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515448
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526409
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
Study: NCT00526409
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
Study: NCT00526409
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
Study: NCT00414271
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
Study: NCT01623622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once or more / week
Study: NCT02603952
Drug: MEDI8852
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
Study: NCT02629549
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of OTL38 prior to surgery
Study: NCT00531934
Drug: Doxycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg po daily
Study: NCT00626704
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
Study: NCT04616196
Drug: NKTR-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 IV every 21 days
Study: NCT00540657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, twice daily, 13 weeks
Study: NCT00429806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03830528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study cohorts (except Part C) are placebo controlled.
Study: NCT02127996
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT02184273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03519178
Drug: Endocrine Therapy 1
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endocrine Therapy 1
Study: NCT03519178
Drug: Endocrine Therapy 2
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endocrine Therapy 2
Study: NCT03561506
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
Study: NCT00858195
Drug: Indomethacin 75mg Extended-Release Capsules, Sandoz
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00858195
Drug: Indocin 75mg SR Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00306748
Drug: MD-1100 Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199157
Drug: Fentanyl transdermal patch
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
Study: NCT02315703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Study: NCT00805298
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets before surgery, one tablet twice daily on the day after surgery
Study: NCT00805298
Drug: xyloplyin adrenalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
Study: NCT00805298
Drug: marcain adrenalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
Study: NCT00391690
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
Study: NCT01851070
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04339764
Drug: iPSC-derived RPE/PLGA transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: iPSC-derived RPE/PLGA transplantation
Study: NCT00290056
Drug: Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 gram oral supplementation for 6 months.
Study: NCT03324477
Drug: hypertonic saline 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
Study: NCT01055223
Drug: TZD only (RSG or PIO or troglitazone)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
Study: NCT01055223
Drug: TZD + spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days.
Study: NCT01055223
Drug: TZD + amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days.
Study: NCT00115752
Drug: Valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00115752
Drug: COX Inhibitor
Normalized name: COX inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02772107
Drug: first-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
Study: NCT01131858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02903355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
Study: NCT00935948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
Study: NCT01346540
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibitor
Study: NCT01346540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 placebo
Study: NCT05898451
Drug: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: has a direct antitumor effect in vitro and in vivo on various tumor cell lines
Study: NCT05898451
Drug: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
Study: NCT02437383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
Study: NCT03505723
Drug: Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
Study: NCT01056029
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Study: NCT01130025
Drug: Innohep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
Study: NCT01102270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule prior to sleep
Study: NCT03133130
Drug: BMT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT101 is administered to 6 subjects in each of 4 groups.
Study: NCT03133130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered to 2 subjects in each of 4 groups.
Study: NCT02182739
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets or injectable solution
Study: NCT02707107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03855865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (prefilled syringe, weekly IV administration or oral daily).
Study: NCT02359604
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA
Study: NCT03469934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered on Day 1 over 1 hour by IV infusion
Study: NCT03185871
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
Study: NCT02284516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match active treatment, BID for 84 days
Study: NCT01624337
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
Study: NCT03929510
Drug: 14C-PF-06651600 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
Study: NCT02633813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for two weeks
Study: NCT02633813
Drug: Naftin® 2% (Naftifine hydrochloride 2%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for two weeks
Study: NCT00660673
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
Study: NCT02217722
Drug: Antibiotic cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study: NCT02957279
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the sepsis group, antibiotics were used when needed.
Study: NCT00713817
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT00713817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
Study: NCT01161641
Drug: ODSH at 0.125 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
Study: NCT01161641
Drug: ODSH at 0.375 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
Study: NCT01161641
Drug: ODSH at 0.250 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
Study: NCT01305083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00669656
Drug: Prostate Health Cocktail
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules daily PO up 12 months
Study: NCT02293161
Drug: GSK2618960
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
Study: NCT02293161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is Sodium Chloride Intravenous Infusion
Study: NCT00885287
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
Study: NCT03602430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
Study: NCT01742000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Study: NCT03776032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
Study: NCT00241358
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02460705
Drug: Biologically active human fecal material, OpenBiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplant